Your session is about to expire
← Back to Search
Part 1: Dose Escalation for Solid Tumors
Study Summary
This trial aims to find out if JNJ-87704916 is safe and effective when used alone or with cetrelimab.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the safety profile of Part 1: Dose Escalation in individuals undergoing treatment?
"Part 1: Dose Escalation is rated as a 1 on the safety scale by our team at Power. This designation reflects the early Phase 1 nature of the trial, where data supporting both safety and efficacy are still limited."
Is this clinical trial currently accepting new participants?
"As per the details on clinicaltrials.gov, this medical investigation is currently seeking suitable participants. The trial was initially listed on 3/25/2024 and had its most recent update on 3/26/2024."
What is the total number of participants being recruited for this research study?
"Affirmative. Information available on clinicaltrials.gov indicates that this trial is actively seeking participants. Initially posted on March 25, 2024, and last revised on March 26, 2024, the study aims to enroll a total of 66 patients from one designated site."
Share this study with friends
Copy Link
Messenger